Multi-omics characterization of immune triggers in Moyamoya disease
The project investigates the link between immune responses to infections and the onset of Moyamoya disease in RNF213 mutation carriers using a multi-omics approach to uncover underlying mechanisms.
Projectdetails
Introduction
This project aims to characterize a recently discovered link between a rare genetic disorder of the brain, called Moyamoya disease (MMD), and the cellular immune response against microbial infections. MMD is characterized by a progressive occlusion of arteries at the base of the brain leading to stroke. Mutations in Ring Finger Protein 213 (RNF213) represent the most common genetic cause of MMD; however, it is suggested that environmental stimuli are needed to trigger disease onset in genetic carriers.
Discovery of RNF213
Intriguingly, we recently discovered RNF213 as a novel antibacterial protein that can target intracellular Listeria (Gram+), providing strong protection to Listeria both in vitro and in vivo.
Interaction with Other Pathogens
Similarly, RNF213 can bind intracellular Salmonella (Gram-), mediating its ubiquitin-dependent degradation. Moreover, we also identified RNF213 as a cellular sensor for proteins modified by ISG15 (ISGylated proteins), a ubiquitin-like modification of the immune system induced by interferon.
Implications of Findings
These observations not only uncover RNF213 as a novel key antimicrobial protein, but they also suggest an important role for the immune system in triggering MMD.
Hypothesis
MULTIMOYA starts from the hypothesis that dysregulated immune responses to infections might trigger MMD disease onset in patients carrying mutations in RNF213.
Research Approach
To investigate this hypothesis, we will:
-
Determine whether MMD patient-derived immune cells respond differently to:
- Interferon
- LPS
- Bacterial infection
-
Map altered pathways using a multi-omics approach, combining:
- Genomics
- Transcriptomics
- Proteomics
- (Tracer) metabolomics data
Validation of Results
Results will be validated by biochemical and imaging analysis in relevant patient-derived/like cellular models as well as in mouse models of MMD that we will establish.
Conclusion
Together, these experiments will provide unprecedented insight into MMD-related immune responses and fundamental processes that link cellular immunity with vascular disease.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.981.593 |
Totale projectbegroting | € 1.981.593 |
Tijdlijn
Startdatum | 1-8-2023 |
Einddatum | 31-7-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- VIB VZWpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Unravelling the role of neuronal antibodies and innate immunity partnership in human autoimmune encephalitisImmuBRAIN aims to uncover the interplay between adaptive and innate immune responses in NMDAR encephalitis to develop novel therapies that enhance recovery and patient outcomes. | ERC Starting... | € 1.499.625 | 2025 | Details |
Molecular Imaging to Guide Repair and Advance Therapy: Targeting the inflammation-fibrosis axis in ischemic heart disease and remote organsMIGRATe aims to optimize imaging-guided, molecular-targeted therapies for improved cardiac repair post-myocardial infarction while assessing inter-organ communication effects. | ERC Consolid... | € 1.933.148 | 2025 | Details |
Do T cells link loss and gain-of-function mechanism in C9orf72 ALS/FTD?This project investigates the role of T cells in the pathogenesis of ALS and FTD due to C9orf72 mutations, aiming to uncover mechanisms for new biomarkers and therapeutic targets. | ERC Starting... | € 1.498.610 | 2024 | Details |
The function of B cells in myocardial infarction-accelerated atherosclerosisThis project aims to investigate glucocorticoid signaling in B cells post-myocardial infarction to identify therapeutic targets for preventing accelerated atherosclerosis in cardiovascular disease. | ERC Starting... | € 1.475.638 | 2023 | Details |
Unveiling the functional outcome of single nucleotide polymorphisms and variants in oligodendroglia in multiple sclerosisThis project aims to explore the active role of oligodendroglia in multiple sclerosis by analyzing SNPs/variants through single-cell omics and CRISPR editing to identify therapeutic targets. | ERC Advanced... | € 3.182.846 | 2024 | Details |
Unravelling the role of neuronal antibodies and innate immunity partnership in human autoimmune encephalitis
ImmuBRAIN aims to uncover the interplay between adaptive and innate immune responses in NMDAR encephalitis to develop novel therapies that enhance recovery and patient outcomes.
Molecular Imaging to Guide Repair and Advance Therapy: Targeting the inflammation-fibrosis axis in ischemic heart disease and remote organs
MIGRATe aims to optimize imaging-guided, molecular-targeted therapies for improved cardiac repair post-myocardial infarction while assessing inter-organ communication effects.
Do T cells link loss and gain-of-function mechanism in C9orf72 ALS/FTD?
This project investigates the role of T cells in the pathogenesis of ALS and FTD due to C9orf72 mutations, aiming to uncover mechanisms for new biomarkers and therapeutic targets.
The function of B cells in myocardial infarction-accelerated atherosclerosis
This project aims to investigate glucocorticoid signaling in B cells post-myocardial infarction to identify therapeutic targets for preventing accelerated atherosclerosis in cardiovascular disease.
Unveiling the functional outcome of single nucleotide polymorphisms and variants in oligodendroglia in multiple sclerosis
This project aims to explore the active role of oligodendroglia in multiple sclerosis by analyzing SNPs/variants through single-cell omics and CRISPR editing to identify therapeutic targets.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial InfarctionTargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation. | EIC Pathfinder | € 3.999.840 | 2023 | Details |
Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair InterventionsCARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes. | EIC Pathfinder | € 4.349.410 | 2023 | Details |
A Multi-Omics Approach for Novel Drug Targets, Biomarkers and Risk Algorithms for Myocardial Infarction
TargetMI aims to rapidly discover novel drug targets and biomarkers for myocardial infarction using a high-throughput multi-omic approach on 1000 samples, enhancing clinical risk prediction and translation.
Comprehensive Analysis of RBM20-induced Dilated Cardiomyopathies using Omics Approaches and Repair Interventions
CARDIOREPAIR aims to identify and therapeutically target RBM20 mutations in dilated cardiomyopathy using high-throughput genomics and bioengineering to improve heart health outcomes.